Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

EGFR High Copy Number Together With High EGFR Protein Expression Predicts Improved Outcome for Cetuximab-based Therapy in Squamous Cell Lung Cancer: Analysis From SWOG S0819, a Phase III Trial of Chemotherapy With or Without Cetuximab in Advanced NSCLC

Clinical Lung Cancer(2021)10.1016/j.cllc.2021.10.002Source: DataRank Database

EGFR High Copy Number Together With High EGFR Protein Expression Predicts Improved Outcome for Cetuximab-based Therapy in Squamous Cell Lung Cancer: Analysis From SWOG S0819, a Phase III Trial of Chemotherapy With or Without Cetuximab in Advanced NSCLC is a research paper published in Clinical Lung Cancer (2021). On theSindex it has a DataRank of 0.659. It has been cited 13 times, with 10 citing works in its 1-hop citation network.

N/A

0.659DataRank · unranked

Scored on demand from live citation data

Deposits data Open Access13 citations · 10 citing works in its network

Download PDF

Cite:

Linked data & code

nct

Data availability

Repositories this paper deposited data in (declared in PubMed).

ClinicalTrials.govNCT00946712

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (8 grants)Impact (FWCI 1.30)OA: greenTopics (52)IDs (PubMed, PMC, OpenAlex)Annotations (1)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

DataRank Breakdown

Base Score 60%Citation Network 40%

Base Score Contribution

0.396

From this paper's citation signal

Citation Network Contribution

0.263

From 8 citing papers with measurable signal

Learn more about DataRank methodology →

Top 5 citers driving the network score

Ranked by each citer's contribution to N(p) — log1p(C_q) divided by its reference count — out of 10 citers.

Elevation of Neutrophil-to-Lymphocyte Ratio Is a Significant Poor Prognostic Factor in Completely Resected Centrally Located Lung Squamous Cell Carcinoma
In Vivo20227 citations20 referencesContributes 0.104
Customised design of antisense oligonucleotides targeting EGFR driver mutants for personalised treatment of non-small cell lung cancer
EBioMedicine202411 citations31 referencesContributes 0.080
Prognostic Impact of EGFR Amplification and Visceral Pleural Invasion in Early Stage Pulmonary Squamous Cell Carcinomas Patients after Surgical Resection of Primary Tumor
Cancers20227 citations58 referencesContributes 0.036
Nuclear epidermal growth factor receptor as a therapeutic target
Exploration of Targeted Anti-tumor Therapy202311 citations96 referencesContributes 0.026
Identification and Application of Emerging Biomarkers in Treatment of Non-Small-Cell Lung Cancer: Systematic Review
Cancers202432 citations150 referencesContributes 0.023

Authors (11)

Mary W. Redman ORCID,James Moon ORCID,Francesco Agustoni ORCID,Roy S. Herbst ORCID,Thomas J. Semrad ORCID

Live enrichment

PubMed:34753703 PMC:PMC8766941 OpenAlex:https://openalex.org/W3205352786

National Cancer Institute

Grant: U10CA180819

National Cancer Institute

Grant: U10CA180846

National Cancer Institute

Grant: U10CA180888

NCI NIH HHS

Grant: P30 CA093373

NCATS NIH HHS

Grant: UL1 TR001863

NCI NIH HHS

Grant: UG1 CA233340

Eli Lilly and Company

National Institutes of Health

FWCI

1.30

Citation Percentile

0.8%

Citation Trend

2022

2023

2024

2025

2026

greenLicense: https://doi.org/10.15223/policy-004

repositoryhttps://www.ncbi.nlm.nih.gov/pmc/articles/8766941

publisherhttps://api.elsevier.com/content/article/PII:S1525730421002631?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S1525730421002631?httpAccept=text/plain

journalhttps://doi.org/10.1016/j.cllc.2021.10.002

Fields of Study

Lung Cancer Treatments and MutationsCancer Immunotherapy and BiomarkersRadiomics and Machine Learning in Medical ImagingAdultAgedAged, 80 and overAntineoplastic Agents, ImmunologicalCarcinoma, Non-Small-Cell LungCetuximabErbB ReceptorsFemaleForecastingGene ExpressionHumansLung NeoplasmsMaleMiddle AgedTreatment OutcomeYoung Adult

MeSH Terms

CetuximabAntineoplastic Agents, ImmunologicalAdultAgedAged, 80 and overCarcinoma, Non-Small-Cell LungFemaleForecastingHumansLung NeoplasmsMaleMiddle AgedGene ExpressionTreatment OutcomeYoung AdultErbB Receptors

Keywords

KRASCetuximabMedicineInternal medicineOncologyLung cancerImmunohistochemistryPanitumumabChemotherapyEpidermal growth factor receptorEGFR inhibitorsCancerColorectal cancerSurvival analysisEgfr AntibodiesEgfr FishEgfr Ihc

Sustainable Development Goals

SDG 0: Life below water

Related Papers (1)

Antisense Oligonucleotides for the Study and Treatment of ALS

Neurotherapeutics(2022)

co-cited

10.1007/s13311-022-01247-2

EGFR High Copy Number Together With High EGFR Protein Expression Predicts Improved Outcome for Cetuximab-based Therapy in Squamous Cell Lung Cancer: Analysis From SWOG S0819, a Phase III Trial of Chemotherapy With or Without Cetuximab in Advanced NSCLC

FAIR Checklist

DataRank Breakdown

Top 5 citers driving the network score

Authors (11)

Funding (8 grants)

Impact

Open Access

Topics

Annotations (Europe PMC)

Related Papers (1)